[[{“value”:”As a cannabis epidemiologist with fifteen years of experience studying cannabis — and as a medical cannabis patient myself — I’ve spent a lot of time thinking about how science assesses and labels cannabis use. For medical patients, cannabis oftenreplaces more harmful medications,reduces pain, and improves quality of life
It is also one of the few treatments shown to have a wide range oftherapeutic effects, reducing the prescription cascade and polypharmacy often seen in individuals with comorbid conditions. Yet, when we use cannabis daily to manage symptoms, we’re at risk of beinglabeled with Cannabis Use Disorder (CUD), a term that is deeply discriminatory when applied to legitimate medical use.
Why is it that patients who take prednisone, insulin, antidepressants, statins, glucagon-like peptide-1s and a myriad of other medications daily or regularly to manage chronic conditions don’t face the same scrutiny? They depend on those medications to function and live more normally and require continuous chronic use for their condition. And withdrawal, if possible, makes symptoms worse. Even after decades of experience, these “side effects” are rarely discussed as they are greatly outweighed by overall benefits.
Medical cannabis users like myself similarly depend on cannabis for improved quality of life. This double standard reflects a lingering stigma around cannabis that is overdue for change. Even when reviewing the literature on cannabis and examining NIH funding priorities for cannabis research, the overwhelming priority is on CUD.
One of the criteria for Cannabis Use Disorder in the DSM-5 (the diagnostic manual for mental health conditions) is using cannabis in larger amounts or over a longer period than intended. But for medical patients, daily use is often prescribed or self-administered, just like any other medication. The goal isn’t recreational enjoyment but relief from debilitating symptoms. We need to rethink how the applicability of the symptoms of CUD as defined by the DSM-5 relate to medical cannabis users and the possibility that “these criteria may not be the most suitable assessment of potential medical cannabis dependence,” according to a university study in England.
Take my own case as an example: I use medical cannabis to manage complex health issues that have not adequately responded to traditional pharmaceuticals. Cannabis allows me to function at a high level enabling me to work, conduct research and live my life somewhat normally. And yet my daily cannabis use might qualify as “disordered” under the current DSM diagnostic framework, while my daily use of Celebrex for joint pain does not. Celebrex Use Disorder just sounds ridiculous.
That inconsistency isn’t just frustrating; it’s harmful. It pathologizes legitimate and effective medical treatment, and could consequently discourage patients from accessing a treatment that could improve their illness and quality of life.
Instead of labeling medical cannabis use as disordered due to frequency of use or tolerance, we should evaluate it through a harm reduction lens — one that prioritizes minimizing risks while maximizing benefits. Harm reduction focuses on outcomes: does cannabis improve the patient’s ability to function, fulfill their roles and enhance their quality of life?For most medical users, the answer is yes.Tailored Dosing
Patients can collaborate with healthcare providers to determine the right dosage, frequency and strain to meet their unique needs while minimizing risks.
CBD Emphasis
Using cannabidiol (CBD)-dominant strains or formulations with low tetrahydrocannabinol (THC) can reduce psychoactive effects while maintaining therapeutic benefits.
Education
Patients should be informed about potential interactions, side effects and safe usage practices.
Rather than stigmatizing tolerance or dose escalation, we should view these as normal physiological responses in a therapeutic context, like those seen with opioids, antidepressants or insulin.
This approach also acknowledges individual needs. Some patients may require higher doses or more frequent use based on their condition or their genetics (yes, your genes play a significant role in how you respond to cannabis), just as with other medications. Rather than stigmatizing tolerance or dose escalation, we should view these as normal physiological responses in a therapeutic context.
Harm reduction doesn’t ignore risks; instead, it emphasizes education and safety. For example, patients can work with healthcare providers to use cannabis in ways that minimize side effects, avoid negative interactions and optimize symptom control. This perspective balances safety with patient autonomy and respects cannabis as a legitimate medicine.
Recognizing the Limits of Medical Cannabis
While cannabis has considerable therapeutic potential, it’s not a panacea. Many of us — myself included — still rely on traditional medicines to manage complex health conditions. For many, cannabis works best as an adjunct therapy, complementing other treatments and, in some cases, reducing reliance on more harmful medications, such as opioids.
For some individuals, however, cannabis use can pose risks that outweigh its benefits:
Psychosis and Mental Health Conditions
Cannabis, particularly THC-rich strains, can exacerbate psychosis or increase the risk of developing psychotic symptoms. This is especially true for individuals with a diagnosis of psychosis, schizophrenia or a family history of psychotic disorders. THC interacts with brain pathways that can heighten vulnerability in those already predisposed. For such individuals, avoiding cannabis — or opting for formulations with high CBD and minimal THC — may be safer.
Substance Use Disorders
People with active or remitting substance use disorders should approach cannabis cautiously. While some may find it helpful for harm reduction (e.g., as a substitute for opioids), others may be at risk of developing problematic use patterns. Close monitoring and guidance from healthcare providers are essential in these cases.
Children and Adolescents
Routine cannabis use is not recommended for children or adolescents except in specific medical contexts, such as treatment-resistant epilepsy But early exposure to THC can interfere with brain development and potentially increase the risk of mental health challenges later in life. Adults should use cannabis responsibly and avoid exposing children to its effects.
Pregnancy
Cannabis use during pregnancy is a complex and controversial topic. While some pregnant individuals may consider cannabis to alleviate nausea, vomiting or anxiety, research indicates potential risks to fetal development. Studies suggest that cannabis use during pregnancy, particularly THC exposure, may impact brain development, leading to long-term effects on cognition, behavior and attention in children. Pregnant individuals experiencing severe symptoms like hyperemesis gravidarum should consult their healthcare provider to explore safer, evidence-based alternatives.
“Frequent cannabis use increases the risk of dependence, regardless of intent.”
Dependence is a normal response to consistent use of any medication, whether it’s cannabis, statins, insulin or antidepressants. The key is whether the use is therapeutic and improves the patient’s quality of life.For many medical cannabis users, this is the case.
“Medical cannabis users might still develop Cannabis Use Disorder (CUD).”
Yes, medical cannabis users are at higher risk for CUD under its current definition. For those at higher risk (e.g., with substance use disorders or mental health vulnerabilities), a personalized harm reduction approach can help ensure cannabis use is safe and effective.
“Cannabis isn’t a ‘real’ medicine. It’s not FDA-approved for most conditions.”
Cannabis’s regulatory status is due to outdated policies that need to be revised, not lack of evidence. Studies increasingly show its efficacy for conditions like chronic pain, anxiety nausea, appetite seizure disorders. The FDA has approved Epidiolex, which contains a purified form of CBD for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.
“Tolerance and dose escalation make cannabis a dangerous treatment.”
Tolerance is not unique to cannabis; it’s a normal response to many medications. Patients on opioids, benzodiazepines or even insulin may require dose adjustments over time; personalized precision dosing is dependent on disease state and patient response. If adjustments are supervised and effective, they’re no more dangerous than changes in other treatments.
“Cannabis is addictive and harmful, so it should be monitored closely.”
While any substance can be harmful if misused — Remember when Tide pods were all the rage? — cannabis is far less addictive than opioids and many other commonly prescribed medications. For medical users, cannabis often replaces more harmful drugs, reducing overall risk. Careful monitoring is still essential for vulnerable populations to maximize benefits while minimizing risks.
It’s time to move beyond outdated stigmas and recognize medical cannabis for what it is: a legitimate medicine. Instead of pathologizing its use, we should focus on outcomes like improved functionality, decreasing reliance on riskier medications, reduced suffering and enhanced quality of life.
By integrating a harm reduction approach into our evaluation of cannabis, we can ensure that patients are treated with the same respect as those using any other treatment. The way we label cannabis use has real consequences. It shapes perceptions, guides policy and impacts access.
Let’s start treating medical cannabis like what it is: a tool for healing, not a cause for judgment.
Joanna Zeiger, MS, Ph.D., is the founder and CEO of Canna Research Foundation, a nonprofit organization dedicated to conducting, promoting and consulting on scientific cannabis research. She is also an Olympian and former World Champion in triathlon.
Westword.com publishes commentaries on matters of interest to the community on the weekends; the opinions expressed in these pieces are those of the authors, not Westword. Have one you’d like to submit? Send it to [email protected], where you can also comment on this commentary.
“}]] “Why is it that patients who take prednisone, insulin…and a myriad of other medications daily or regularly to manage chronic conditions don’t face the same scrutiny? Read More
